First Quadrant’s KalVista Pharmaceuticals KALV Stock Holding History

First Quadrant’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-2,434	Closed	-$54K	–	631
2019 Q2	$54K	Sell	2,434 -572	-19%	-$13.4K	﹤0.01%	624
2019 Q1	$86K	Sell	3,006 -48	-2%	-$1.04K	0.01%	600
2018 Q4	$60K	Hold	3,054	–	–	﹤0.01%	710
2018 Q3	$68K	Sell	3,054 -1,549	-34%	-$20.9K	﹤0.01%	753
2018 Q2	$37K	Hold	4,603	–	–	﹤0.01%	717
2018 Q1	$44K	Sell	4,603 -1,247	-21%	-$13.1K	﹤0.01%	751
2017 Q4	$57K	Sell	5,850 -3,400	-37%	-$35.4K	﹤0.01%	836
2017 Q3	$62K	Sell	9,250 -1,600	-15%	-$11.4K	﹤0.01%	827
2017 Q2	$80K	Hold	10,850	–	–	﹤0.01%	786
2017 Q1	$85K	Sell	10,850 -1,900	-15%	-$14.3K	﹤0.01%	706
2016 Q4	$90K	Hold	12,750	–	–	﹤0.01%	710
2016 Q3	$82K	Sell	12,750 -2,014	-14%	-$15.2K	﹤0.01%	743
2016 Q2	$137K	Buy	+14,764	New	+$171K	﹤0.01%	624

Other funds holding KALV

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Quadrant's KALV Position: Q3 2019 in Review

First Quadrant sold out of KalVista Pharmaceuticals (KALV) in Q3 2019, closing a stake of 2,434 shares — an estimated $54K sold.

First Quadrant first reported a position in KALV in Q2 2016 and held it in 13 quarters. The position peaked at $137K in Q2 2016. 76 funds tracked by Wall St. Rank hold KALV as of Q3 2019.

First Quadrant reported no remaining KalVista Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
First Quadrant sold 2,434 KalVista Pharmaceuticals shares in Q3 2019, an estimated $54K.
First Quadrant first reported a position in KalVista Pharmaceuticals in Q2 2016 and held it in 13 quarters.
First Quadrant's KalVista Pharmaceuticals position peaked at $137K in Q2 2016.
76 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2019.

Based on First Quadrant's 13F filing for Q3 2019, filed 25 Oct 2019.